Project Grant HT94252410381

Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $501,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 15, 2025, with a completion date of July 14, 2027. The research project, titled "Large Oncosomes as Drivers of Prostate Cancer Bone Metastasis," is being conducted at the institution's West Hollywood, California location. This award supports biomedical...

Grant Summary The National Cancer Institute awarded Cedars-Sinai Medical Center a Project Grant of $523,670 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective September 12, 2025, with completion targeted for August 31, 2029. The award supports the development and validation of an artificial intelligence (AI) tumor detection model designed to improve early-stage identification of pancreatic ductal adenocarcinoma (PDAC) through analysis of abdominal computed...

The Department of the Army Medical Command awarded Cedars-Sinai Medical Center a $1,252,233 Project Grant on September 30, 2022 to support research titled "NOVEL LINEAGE PLASTICITY INHIBITORS IN PROSTATE CANCER." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research solutions for battlefield medicine and other health issues. Under this award, Cedars-Sinai...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...

Cedars-Sinai Medical Center will utilize $667,998 in funding from the Department of the Army Medical Command under the Military Medical Research and Development program to support the project "A Deep Learning Strategy to Integrate Karyometric Features with Underlying Molecular Pathways in Ovarian Cancer Initiation" from August 1, 2022 to July 31, 2026. Through this Project Grant award, Cedars-Sinai Medical Center will conduct research to develop a deep learning strategy to integrate...

This Project Grant award from the Defense Health Agency provides $825,000 in funding to Fundacio Privada Institut D Investigacio Oncologica De Vall-Hebron for studying intratumor heterogeneity in the evolution of metastatic hormone-naive prostate cancer to castration resistance after intensified hormonal therapy. The award period runs from April 1, 2023 through May 31, 2027. The funding supports research under the Military Medical Research and Development program (CFDA 12.420), which aims to...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded Cedars-Sinai Medical Center a Project Grant of $429,399 under the Cancer Treatment Research program (CFDA 93.395) on August 18, 2025, with a completion date of July 31, 2027. This R21 grant supports a two-investigator research initiative investigating the role of extracellular vesicles (EVs) enclosed circular RNA (circRNA) in modulating immune responses within the prostate cancer tumor microenvironment. The research...

This federal Project Grant award of $627,474.00 from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports a research project titled "Mapping the Epigenetic Dynamics of Prostate Cancer Progression: Integrating Liquid Biopsies and Single-Cell Epigenomics for Early Detection of Lineage Plasticity and Clinical Decision-Making." The project aims to utilize innovative epigenomic methods and signatures to better understand...

Federal Grant Award Summary The National Cancer Institute awarded a $684,107 Project Grant to Massachusetts General Hospital (The General Hospital Corporation) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on August 18, 2025, with completion anticipated by July 31, 2030. The grant funds research integrating circulating tumor cell (CTC) biomarkers with nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA)...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...